Towards Healthcare
Medroxyprogesterone Acetate (MPA) Market to Grow at 9.13% CAGR till 2034

Medroxyprogesterone Acetate (MPA) Market Expands Amid 2025 Demand

Based on market forecasts, the medroxyprogesterone acetate (MPA) sector will expand from USD 1.14 billion in 2024 to USD 2.75 billion by 2034, experiencing a CAGR of 9.13%. The rising prevalence of gynecological disorders is estimated to drive the growth of the market. North America led the global market owing to high healthcare expenditure and insurance coverage.

Content

  • Last Updated: 06 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The medroxyprogesterone acetate (MPA) market currently in 2025 records USD 1.24 billion and is anticipated to grow to USD 2.75 billion by 2034, advancing at a CAGR of 9.13% from 2024 to 2034.

North America is leading the medroxyprogesterone acetate (MPA) market due to the growing demand for long-acting contraceptives, the prevalence of gynecological disorders, and government initiatives promoting women health, drive market growth.

Some key players include Pfizer Inc., Bayer AG, Mylan N.V. (Viatris), Cipla Limited, Teva Pharmaceutical Industries Ltd., Hetero Labs Limited, Fresenius Kabi AG, and Sandoz International GmbH etc.

MPA is a synthetic progestin hormone used in contraceptives, hormone replacement therapy, and the treatment of gynecological disorders such as endometriosis and irregular menstruation. It is available in oral tablets, injectable, and subcutaneous formulations.

Personalized Medicine Coalition, The Menopause Society, Government of Canada, Food and Drug Administration, International Menopause Society (IMS), clinicaltrials.gov, North American Menopause Society, WHO, JAMA, GOV.UK
Any Questions